CN109381696A - It is a kind of for preventing and treating the preparation method of the slow-releasing microcapsule of Porcine circovirus desease - Google Patents
It is a kind of for preventing and treating the preparation method of the slow-releasing microcapsule of Porcine circovirus desease Download PDFInfo
- Publication number
- CN109381696A CN109381696A CN201811024012.2A CN201811024012A CN109381696A CN 109381696 A CN109381696 A CN 109381696A CN 201811024012 A CN201811024012 A CN 201811024012A CN 109381696 A CN109381696 A CN 109381696A
- Authority
- CN
- China
- Prior art keywords
- slow
- parts
- porcine circovirus
- preparation
- releasing microcapsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003094 microcapsule Substances 0.000 title claims abstract description 25
- 241000202347 Porcine circovirus Species 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000011782 vitamin Substances 0.000 claims abstract description 15
- 229940088594 vitamin Drugs 0.000 claims abstract description 11
- 108091093037 Peptide nucleic acid Proteins 0.000 claims abstract description 9
- 230000000692 anti-sense effect Effects 0.000 claims abstract description 9
- 229940107666 astragalus root Drugs 0.000 claims abstract description 9
- 229960003080 taurine Drugs 0.000 claims abstract description 9
- 240000004530 Echinacea purpurea Species 0.000 claims abstract description 8
- 235000014134 echinacea Nutrition 0.000 claims abstract description 8
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 claims abstract description 6
- 239000007921 spray Substances 0.000 claims description 12
- 229920001661 Chitosan Polymers 0.000 claims description 11
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 239000004925 Acrylic resin Substances 0.000 claims description 7
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 6
- 239000000600 sorbitol Substances 0.000 claims description 6
- -1 sorbitol anhydride Chemical class 0.000 claims description 6
- 238000001694 spray drying Methods 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 5
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 4
- WIGIZIANZCJQQY-UHFFFAOYSA-N 4-ethyl-3-methyl-N-[2-[4-[[[(4-methylcyclohexyl)amino]-oxomethyl]sulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCC(C)CC2)C=C1 WIGIZIANZCJQQY-UHFFFAOYSA-N 0.000 claims description 4
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 4
- 229930003427 Vitamin E Natural products 0.000 claims description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 4
- 235000019441 ethanol Nutrition 0.000 claims description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 4
- 235000019359 magnesium stearate Nutrition 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 239000011719 vitamin A Substances 0.000 claims description 4
- 235000019155 vitamin A Nutrition 0.000 claims description 4
- 235000019165 vitamin E Nutrition 0.000 claims description 4
- 229940046009 vitamin E Drugs 0.000 claims description 4
- 239000011709 vitamin E Substances 0.000 claims description 4
- 229940045997 vitamin a Drugs 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 241000723353 Chrysanthemum Species 0.000 claims 1
- 235000007516 Chrysanthemum Nutrition 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 229940097411 palm acid Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 14
- 229940079593 drug Drugs 0.000 abstract description 11
- 208000024891 symptom Diseases 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 6
- 238000000034 method Methods 0.000 abstract description 5
- 241001533384 Circovirus Species 0.000 abstract description 3
- 235000019789 appetite Nutrition 0.000 abstract description 3
- 230000036528 appetite Effects 0.000 abstract description 3
- 239000011248 coating agent Substances 0.000 abstract description 3
- 238000000576 coating method Methods 0.000 abstract description 3
- 230000009977 dual effect Effects 0.000 abstract description 2
- 230000000740 bleeding effect Effects 0.000 abstract 1
- 208000033065 inborn errors of immunity Diseases 0.000 abstract 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 241000282898 Sus scrofa Species 0.000 description 14
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 241000700605 Viruses Species 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 6
- 241001673669 Porcine circovirus 2 Species 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- 235000019766 L-Lysine Nutrition 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241001661006 Pepper cryptic virus 2 Species 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 229940031551 inactivated vaccine Drugs 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000254223 Syntexis Species 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000022532 enlargement of lymph nodes Diseases 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a kind of for preventing and treating the preparation method of the slow-releasing microcapsule of Porcine circovirus desease.Slow-releasing microcapsule of the invention is to be prepared using Astragalus Root P.E, Echinacea Purpurea Herb P.E, taurine, antisense peptide nucleic acid, L-lysine, multi-vitamins as raw material by dual coating technique.The present invention has good clinical efficacy to Porcine circovirus desease, can improve the symptoms such as the appetite stimulator for suffering from circovirus sick pig, apathetic, unsmooth breath, scytitis bleeding, hypoimmunity.And there is slow release effect, improve the stability of drug.
Description
(1) technical field
The present invention relates to veterinary drug technical fields, and in particular to a kind of for preventing and treating the system of the slow-releasing microcapsule of Porcine circovirus desease
Preparation Method.
(2) background technique
Pig circular ring virus (PCV) is one of the smallest animal virus found so far.Known PCV there are two serotype,
That is PCV1 and PCV2.PCV1 is the virus of non-pathogenic, and PCV2 is pathogenic virus.It will appear weanling pig after PCV2 infection
Multisystem exhaustion syndrome (PMWS), pigskin inflammation nephrotic syndrome (PNDS), respiratory diseases in pigs mixing disease, breeding difficulty are comprehensive
Sign etc..The meaning of existing " Porcine circovirus desease " (PCVD) refers to group's disease or disease relevant to PCV2.
This disease can lead to swinery and generate serious immunosupress, to be easy to cause secondary or concurrent animal infectious diease.?
With the presence of PCV particle in sick pig schneiderian membrance, bronchus, lungs, tonsillotome, kidney, spleen and small intestine.Thymus gland, spleen, mesenterium,
There is the virus in the lymphoid tissue of bronchus etc., shows the immune system of PCV serious infringement pig.Viral and macrophage/
Monocyte, histocyte and thymus gland macrophage accompany, and affected pig body condition is caused to decline, and form immunosupress.Due to immune
Inhibit and lead to immune deficiency, the microorganism or attenuated vaccine to low pathogenicity can trigger disease, repeat morbidity to treatment nothing
Responsiveness does not have an abundant immune response to vaccine inoculation, and there are many disease syndromes to occur simultaneously in swinery.
Country's prevention and treatment Porcine circovirus desease is mainly treated using vaccine, antibiotic, chemical drug, Chinese herbal medicine etc..At present
It is for reducing or improve piglet PMWS symptom mostly, commercialized vaccine is for pre- in development or the vaccine that has been commercialized
The comprehensive therapeutic effect of anti-PCVD also needs to further look at.Antibiotic, chemical drug and hormone product long-time service can make cause of disease micro-
Biology generates drug resistance, product medicament residue and environmental pollution etc., seriously threatens human health.Chinese herbal medicine due to the place of production is more,
Qualities etc. cause clinical efficacy inaccurate, and existing Chinese herbal medicine is mostly pulvis, inconvenient to use, dosage
Greatly, effective component bioavailability is low, and clinical effectiveness is undesirable.
(3) summary of the invention
The object of the present invention is to provide a kind of compositions for preventing and treating Porcine circovirus desease, solve the prior art and prevent and treat pig annulus
The unconspicuous problem of curative effect of medication existing for virosis.
A second object of the present invention is to provide a kind of preparation methods of slow-releasing microcapsule for preventing and treating Porcine circovirus desease, solve
The problem that existing medicament is not easy to maintain, stability is poor.
In order to solve the above technical problems, the present invention provides a kind of preparation side of slow-releasing microcapsule for preventing and treating Porcine circovirus desease
The supplementary material of method, the slow-releasing microcapsule indicates in parts by weight are as follows:
80~100 parts of Astragalus Root P.E, 80~100 parts of Echinacea Purpurea Herb P.E, 50~80 parts of taurine, antisense peptide nucleic acid 5
~10 parts, 0.3~0.5 part of L-lysine, 0.4~1.2 part of multi-vitamins, 15~20 parts of polyacrylic resin II, sorbierite
0.1~0.2 part of acid anhydride monopalmitate, 200~350 parts of chitosan, 25~40 parts of magnesium stearate.
The multi-vitamins are to be mixed to prepare vitamin A, vitamine D3, vitamin E by 1: 1: 2 weight ratio.
The slow-releasing microcapsule the preparation method is as follows:
It takes polyacrylic resin II to be dissolved in 35~45 DEG C of 95% ethyl alcohol first, antisense peptide nucleic acid is added, L-lysine, answers
Vitamin and sorbitol anhydride monopalmitate are closed, is stirred evenly, 85~95 DEG C of spray drying, spray powder crosses 80~100 meshes
It is spare；It takes Astragalus Root P.E, Echinacea Purpurea Herb P.E, taurine to be dissolved in water again, filters, filtrate is spare；Separately take chitosan with 1~
2% acetum is configured to 2~4% chitosan solution, and above-mentioned filtrate, spray powder and magnesium stearate is added, stirs evenly,
140~160 DEG C spray drying to get.
The present invention carries out dialectical prescription for PCVD clinical symptoms, using more in Astragalus Root P.E and Echinacea Purpurea Herb P.E
The raising body specificity and non-specific immunity that sugar, saponin(e, organic acid ingredient have, improve affected pig immunodeficiency symptoms
Shape.Antisense peptide nucleic acid can act on viral RNA, and the duplication of blocking virus gene reaches treatment virosis purpose.Taurine,
L-lysine and multi-vitamins can improve the various clinical symptom of affected pig.All medicines share can solve many clinics of PCVD
Symptom.Since the absorption features of different pharmaceutical in the gastrointestinal tract are different, the utilization of drug can be improved using dual coating technique
Degree, and there is slow release effect.The stability of drug can be also improved by coating technique.
(4) specific embodiment:
The present invention is described in further detail by following embodiment, but is not limited to the present embodiment.
Embodiment 1: it is a kind of for preventing and treating the preparation method of the slow-releasing microcapsule of Porcine circovirus desease, weigh polyacrylic resin
II 18g is dissolved in 95% ethyl alcohol of 250ml (40 DEG C), and antisense peptide nucleic acid 8g, L-lysine 0.5g, multi-vitamins is added
1.2g (wherein vitamin A 0.3g, vitamine D3 0.3g, vitamin E 0.6g) and sorbitol anhydride monopalmitate
0.15g is stirred evenly, and is placed in spray dryer, and with intake air temperature for 90 DEG C, spray drying, it is standby that spray powder crosses 80 meshes
With；It takes Astragalus Root P.E 80g, Echinacea Purpurea Herb P.E 100g, taurine 60g that 2000ml water is added to dissolve again, filters, filtrate is spare；
Separately chitosan 220g is taken to be configured to 3% chitosan solution with 1.4% acetum, above-mentioned filtrate, spray powder and tristearin is added
Sour magnesium 30g, stirs evenly, is placed in spray dryer, with intake air temperature for 150 DEG C, is spray-dried to get slow-releasing microcapsule
One.
Embodiment 2: it is a kind of for preventing and treating the preparation method of the slow-releasing microcapsule of Porcine circovirus desease, weigh polyacrylic resin
II20g is dissolved in 95% ethyl alcohol of 300ml (45 DEG C), and antisense peptide nucleic acid 10g, L-lysine 0.4g, multi-vitamins is added
0.8g (wherein vitamin A 0.2g, vitamine D3 0.2g, vitamin E 0.4g) and sorbitol anhydride monopalmitate
0.14g is stirred evenly, and is placed in spray dryer, and with intake air temperature for 95 DEG C, spray drying, it is standby that spray powder crosses 80 meshes
With；It takes Astragalus Root P.E 100g, Echinacea Purpurea Herb P.E 100g, taurine 80g that 2200ml water is added to dissolve again, filters, filtrate is spare；
Separately chitosan 300g is taken to be configured to 4% chitosan solution with 1.6% acetum, above-mentioned filtrate, spray powder and tristearin is added
Sour magnesium 35g, stirs evenly, is placed in spray dryer, with intake air temperature for 160 DEG C, is spray-dried to get slow-releasing microcapsule
Two.
(such as CN201711242311.9 is a kind of to treat pig circular ring virus 2 to technical solution of the present invention compared with other technologies scheme
Composition of viral disease and preparation method thereof), Chinese medicine, biological products and nutritional ingredient are combined in prescription compatibility, make the present invention
Technical solution it is more preferable to PCVD therapeutic effect.
Laboratory effect of drugs is investigated
By 35 age in days Ternary Pig ternary commodity piglet 40,5 groups are randomly divided by weight, every group 10, is respectively sustained
One group of micro-capsule, two groups of slow-releasing microcapsule, technical solution (a kind of composition for treating Porcine circovirus desease of CN201711242311.9 and
Preparation method) group, immunized controls group, after each group adaptive feeding 1 week, neck intramuscular injection PCV-2 type inactivated vaccine after ear.
Each test group immune same day adds 0.5% drug mixed feeding in feed respectively, continuous feeding 1 week；Immunized controls group is not given
Drug, the test period 30 days.Respectively at being immunized first 1 day and testing the 30th day, the blood sampling of each group test pig vena cava anterior separates blood
Clearly, PCV antibody level is detected using ELISA kit.
Test result is shown in Table 1.
1 each group serum antibody titer measurement result (OD value) of table
| Group | It is immunized first 1 day | It tests the 30th day |
| One group of slow-releasing microcapsule | 0.65±0.21 | 1.16±0.25b |
| Two groups of slow-releasing microcapsule | 0.64±0.22 | 1.20±0.30b |
| Technical solution group | 0.63±0.21 | 1.06±0.26 |
| Immunized controls group | 0.64±0.23 | 0.86±0.29a |
Note: lowercase difference indicates significant difference (P < 0.05).
The above results explanation, slow-releasing microcapsule of the invention can extend the antibody level of PCV-2 type inactivated vaccine, and immune
Control group comparing difference is significant (P < 0.05).
In order to further verify the therapeutic effect of slow-releasing microcapsule of the invention, the clinical examination for suffering from circovirus sick pig has been carried out
It tests.
For trying place: Henan Province, pig farm, Shangqiu City Xiayi County.
35 age in days piglet 1200 is bought at the beginning of in Augusts, 2017, anorexia occurs in piglet after feeding 2 weeks, spiritual depressed, happiness is crouched,
Expiratory dyspnea, pachylosis, coat are fluffy and disorderly, thin, later period failure is dead.Dissect discovery, the main pathological change of sick dead pig are
There are inflammation, liver obfuscation, kidney oedema, the lesions such as pale in syntexis, anaemia, ochrodermia and jaundice, enlargement of lymph nodes, lung.
Not significant, disease incidence 30%, death and culling rate 8.5% using antimicrobial progress conventional therapy effect.By clinical diagnosis and reality
Room detection is tested, determines the clinical symptoms that swinery infection circovirus is caused.It gives and adds sustained release of the invention in swinery feed
Micro-capsule one, feed addition 5kg per ton are used continuously the 5th day, and swinery appetite is restored substantially, and spirit improves, and respiratory symptom subtracts
Gently, dead to reduce, successive administration 10 days, swinery smoothing filter operator was cured substantially, and appetite is restored, and the state of mind is good, death and culling rate
It is reduced to 2.4%, cure rate 92.7%.
The above results explanation, slow-releasing microcapsule of the invention have good therapeutic effect to Porcine circovirus desease, illustrate logical
The whole curative effect of drug can be improved in the compatibility for crossing science.
Claims (4)
1. it is a kind of for preventing and treating the preparation method of the slow-releasing microcapsule of Porcine circovirus desease, it is characterized in that by Astragalus Root P.E, purple cone
Chrysanthemum extract, taurine, antisense peptide nucleic acid, L-lysine, multi-vitamins, polyacrylic resin II, sorbitol anhydride list palm
Acid esters, chitosan, magnesium stearate form, their parts by weight are as follows:
80~100 parts of Astragalus Root P.E, 80~100 parts of Echinacea Purpurea Herb P.E, 50~80 parts of taurine, antisense peptide nucleic acid 5~10
Part, 0.3~0.5 part of L-lysine, 0.4~1.2 part of multi-vitamins, 15~20 parts of polyacrylic resin II, sorbitol anhydride list
0.1~0.2 part of palmitate, 200~350 parts of chitosan, 25~40 parts of magnesium stearate.
2. the preparation method of the slow-releasing microcapsule of prevention and treatment Porcine circovirus desease according to claim 1, it is characterised in that described
Multi-vitamins are to be mixed to prepare vitamin A, vitamine D3, vitamin E by 1: 1: 2 weight ratio.
3. the preparation method of the slow-releasing microcapsule of prevention and treatment Porcine circovirus desease according to claims 1 to 2, it is characterised in that system
Preparation Method are as follows: take polyacrylic resin II to be dissolved in 35~45 DEG C of 95% ethyl alcohol first, be added antisense peptide nucleic acid, L-lysine,
Multi-vitamins and sorbitol anhydride monopalmitate, stir evenly, and 85~95 DEG C of spray drying, spray powder crosses 80~100 mesh
It sieves spare；It takes Astragalus Root P.E, Echinacea Purpurea Herb P.E, taurine to be dissolved in water again, filters, filtrate is spare；Separately take chitosan with 1
~2% acetum is configured to 2~4% chitosan solution, and above-mentioned filtrate, spray powder and magnesium stearate is added, stirs evenly,
140~160 DEG C spray drying to get.
4. the slow-releasing microcapsule of any prevention and treatment Porcine circovirus desease stated according to claim 1~3, it is characterised in that can be prepared into mouth
Take liquid and granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811024012.2A CN109381696A (en) | 2018-08-27 | 2018-08-27 | It is a kind of for preventing and treating the preparation method of the slow-releasing microcapsule of Porcine circovirus desease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811024012.2A CN109381696A (en) | 2018-08-27 | 2018-08-27 | It is a kind of for preventing and treating the preparation method of the slow-releasing microcapsule of Porcine circovirus desease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109381696A true CN109381696A (en) | 2019-02-26 |
Family
ID=65418494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811024012.2A Pending CN109381696A (en) | 2018-08-27 | 2018-08-27 | It is a kind of for preventing and treating the preparation method of the slow-releasing microcapsule of Porcine circovirus desease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109381696A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1951382A (en) * | 2006-09-30 | 2007-04-25 | 赵爱国 | Oral formulation of neogambogic acid for treating tumor |
| US20090162398A1 (en) * | 2007-12-21 | 2009-06-25 | Wyeth | Methods and Compositions for Immunizing Pigs Against Porcine Circovirus |
| CN103102397A (en) * | 2011-11-09 | 2013-05-15 | 韩健宝 | Peptide nucleic acid for prevention and treatment of PCV2 virus and preparation thereof |
| CN104274511A (en) * | 2013-07-08 | 2015-01-14 | 洛阳惠中兽药有限公司 | Traditional Chinese medicinal composition for veterinary use and application thereof |
| CN105999231A (en) * | 2016-06-06 | 2016-10-12 | 张英杰 | Polypeptide composition, composition for improving livestock and poultry immune function, and preparation method of composition for improving livestock and poultry immune function |
-
2018
- 2018-08-27 CN CN201811024012.2A patent/CN109381696A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1951382A (en) * | 2006-09-30 | 2007-04-25 | 赵爱国 | Oral formulation of neogambogic acid for treating tumor |
| US20090162398A1 (en) * | 2007-12-21 | 2009-06-25 | Wyeth | Methods and Compositions for Immunizing Pigs Against Porcine Circovirus |
| CN103102397A (en) * | 2011-11-09 | 2013-05-15 | 韩健宝 | Peptide nucleic acid for prevention and treatment of PCV2 virus and preparation thereof |
| CN104274511A (en) * | 2013-07-08 | 2015-01-14 | 洛阳惠中兽药有限公司 | Traditional Chinese medicinal composition for veterinary use and application thereof |
| CN105999231A (en) * | 2016-06-06 | 2016-10-12 | 张英杰 | Polypeptide composition, composition for improving livestock and poultry immune function, and preparation method of composition for improving livestock and poultry immune function |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101455736B (en) | Use of wild jujube seeds extract | |
| JP5744213B2 (en) | Use of arctigenin in the manufacture of a drug for the prevention or treatment of diseases associated with erythropenia | |
| CN102151256A (en) | Application of protocatechuic acid in preparation of drugs for preventing and controlling livestock and poultry virus infectious diseases | |
| CN102274314A (en) | Evergreen coccidian powder and preparation method thereof | |
| CN1857416A (en) | Chinese medicine composition with functions of expelling surficial evils and clearing away head and toxic materials and its preparing method and application | |
| CN105616485A (en) | Doxycycline hydrochloride and origanum oil composition | |
| CN108272874A (en) | Chinese medicine preparation and preparation method thereof for laying hen | |
| CN103768157A (en) | Veterinary antiviral traditional Chinese medicine Ziqi effervescent granules and preparation method thereof | |
| CN109381696A (en) | It is a kind of for preventing and treating the preparation method of the slow-releasing microcapsule of Porcine circovirus desease | |
| CN1958008A (en) | Animal use compound medicament with effects of removing toxic heat, and preparation method | |
| CN106389717A (en) | Piglet drug-resistant colibacillosis treating traditional Chinese medicine composition | |
| CN105343229A (en) | Traditional Chinese medicinal composition for preventing and treating colibacillosis of livestock and poultry, and preparation method thereof | |
| CN102641474B (en) | Compound propolis composition for treating chicken mycoplasmosis and preparation method thereof | |
| CN102813909B (en) | Compound doxycycline hydrochloride composition for preventing and treating colibacillosis and chronic respiratory disease of poultry as well as preparation method thereof | |
| CN104971124A (en) | New application of medicine composition | |
| CN1958023A (en) | Animal use compound medicament with effects for invigorating qi, strengthening the superficial, dispelling wind-evil, and being sensible, and preparation method | |
| CN106265684A (en) | The application of Lupenyl acetate | |
| CN107582753A (en) | A kind of pharmaceutical composition for being used to prevent and treat bronchial astehma | |
| CN113350429A (en) | Traditional Chinese medicine composition for preventing and treating African swine fever disease and preparation method and application thereof | |
| CN116036188B (en) | Traditional Chinese medicine composition for preventing and treating chicken coccidiosis as well as preparation method and application thereof | |
| CN115998798B (en) | Traditional Chinese medicine for treating constipation and preparation method and application thereof | |
| CN104758407A (en) | Traditional Chinese medicine composition for treating hemorrhagic enteritis in turkey and preparation method of traditional Chinese medicine composition | |
| CN108969648A (en) | A kind of pharmaceutical composition and application method | |
| Wang et al. | Effects of modified pulsatilla decoction on avian colibacillosis and concentrations of nitrogen oxide (NO) and tumor necrosis factor-α (TNF-α) in serum | |
| CN103550705B (en) | The composition and method of making the same for the treatment of Infectious Tracheobroncheitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190226 |